Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
ELIXIR
**RECOMMENDED DOSAGE:** Adults and children over 12 years: 2 teaspoonfuls 3 times a day **Children and Adolescents:** Codeine should not be used in children below 12 years old. In those 12 years old and above, codeine may be used for the treatment of unproductive cough which is not relieved by other anti-tussives alone. The lowest effective dose should be used for the shortest possible duration.
ORAL
Medical Information
**INDICATIONS:** Temporary relief of coughs and upper respiratory symptoms including nasal congestion associated with allergy or the common cold.
**CONTRA-INDICATIONS:** In patients intolerant to Pseudoephedrine HCI or Triprolidine HCI or Codeine Phosphate. Patients with severe hypertension, severe coronary artery disease and in patients on MAO inhibitors. FEDAC COMPOUND LINCTUS should not be used in newborn or premature infants and should not be used to treat lower respiratory tract symptoms including asthma.
R05DA20
combinations
Manufacturer Information
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
ICM PHARMA PTE. LTD.
Active Ingredients
Documents
Package Inserts
Att 4 AAAO2079 Fedac Compound Linctus PIL, SG_03 Proposed.pdf
Approved: June 10, 2022